Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression by Castagna, A et al.
Observational Study Medicine®
OPENSwitch of predicted HIV-1 tropism in treated
subjects and its association with disease
progression
Antonella Castagna, MDa,b,∗, Laura Monno, MDc, Stefania Carta, PhDd, Laura Galli, MSca,
Stefania Carrara, PhDd, Valentina Fedele, PhDd, Grazia Punzi, PhDc, Iuri Fanti, MSce, Pietro Caramello, MDf,
Alessandro Cozzi Lepri, PhDg, Andrea De Luca, MDh, Francesca Ceccherini-Silberstein, PhDi,
Antonella d’Arminio Monforte, MDj, On behalf of ICONA Foundation Study GroupAbstract
Dynamics of human immunodeﬁciency virus type 1 (HIV-1) tropism after antiretroviral therapy (ART) initiation and their association
with disease progression are poorly investigated.
This was a cohort study on subjects from the ICONA cohort receiving ART with persistently detectable (PD) or persistently
undetectable (PU) viral load (VL) and with stored plasma or peripheral blood mononuclear cell (PBMC) samples at 2 time-points (T1,
T2) after ART initiation. HIV-1 co-receptor tropism was determined by V3-loop sequencing and the geno2pheno algorithm. A switch
in viral tropism was deﬁned if the tropism classiﬁcation at T2 differed from that observed at T1. Time to disease progression, deﬁned
as the occurrence of a new acquired immune deﬁciency syndrome (AIDS)-deﬁning event/death from T2, was also evaluated.
One hundred ninety-ﬁve patients were analyzed (124 PD, 71 PU). Over a median follow-up of 22.6 (19.8–28.1) months, PD and PU
patients showed similar rates (95% conﬁdence interval) of switch to a non-R5 virus [PD: 6.9 (3.7–11.2)/100-person-years of follow-up
(PYFU); PU: 8.0 (3.4–14.5)/100-PYFU; P=0.63] and of switch to a R5 virus [PD: 15.4 (7.3–26.4)/100-PYFU; PU: 8.1 (2.5–16.7)/100-
PYFU; P=0.38]. Switch to non-R5 virus was predicted by nadir CD4+ before T1.
Twenty-two (18%) PD and 4 (6%) PU subjects experienced disease progression (P=0.02). The risk of disease progression was
independently associated with a switch in co-receptor tropism (adjusted hazard ratio=4.06, 95% CI: 1.20–13.80, P=0.03) as well
as age, AIDS diagnosis, nadir CD4+ before T2, current CD4+, and VL.
Switch of HIV-1 tropism under ART occurs in both directions, with similar rates in subjects with PD or PU VL and it might be
predictive of future unfavorable clinical outcome.
Abbreviations: 95% CI = 95% conﬁdence interval, AIDS = acquired immune deﬁciency syndrome, ART = antiretroviral therapy,
FPR = false positive rate, HCV = hepatitis C virus, HIV-1 = human immunodeﬁciency virus type 1, HR = hazard ratio, IQR =
interquartile range, NNRTI= non-nucleoside reverse transcriptase inhibitor, NRTI= nucleoside reverse transcriptase inhibitor, PBMC
= peripheral blood mononuclear cell, PD = persistently detectable (viral load), PU = persistently undetectable (viral load), PYFU =
person-years of follow-up, RR = relative risk, T1 = time-point 1, T2 = time-point 2, VIF = variance inﬂation factor, VL = viral load.
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Cross-sectional evaluation of human immunodeﬁciency virus
type 1 (HIV-1) co-receptor usage by means of phenotypic assays
and/or V3 population genotyping[1] has been intensively studied
in untreated primary[2] and chronic HIV-1 infection[3,4] and in
patients on virological failure.[5,6] The impact of baseline tropism
on virological response and CD4 gains after antiretroviral
therapy (ART) initiation has also been investigated in several
studies including or not CCR5 inhibitors.[7–9]
The frequency and implications of co-receptor switch in HIV-1
treated subjects unexposed to CCR5 inhibitors are instead poorly
understood. Longitudinal analyses have been performed on co-
receptor usage before and after ART initiation in subjects on
suppressive therapy,[10–15] virological failure,[15–19] or after
therapy interruption,[20,21] yielding controversial results. HIV-
1 co-receptor usage has been determined longitudinally under
ART in paired plasma[16,17] or peripheral bloodmononuclear cell
(PBMC) samples[10,12–15] in a very limited subset of patients.
There are several studies that have evaluated the relationship
between the co-receptor tropism and the risk of clinical
disease progression in ART-naïve subjects or after treatment
initiation,[9,22–24] on the other hand, whether HIV-1 tropism
switch under ART pressure might be associated with the risk of
clinical progression has never been previously investigated.
The aim of this study was to determine the rate of HIV-1
tropism switch in subjects under ART both in presence of
persistently detectable (PD) or undetectable (PU) viral load (VL).
The association between tropism switch and disease progression
was also evaluated.2. Methods
This is a longitudinal cohort study on adult HIV-1 treated
subjects enrolled in the ICONA Foundation Study Cohort, with
available paired samples of plasma or cells stored at 2 time-points
after ART initiation. Brieﬂy, the ICONA Foundation Cohort is a
cohort of HIV-infected patients which superseded the original I.
CO.N.A. (Italian Cohort of Antiretroviral-Naïve Patients) study,
recruiting HIV-positive patients when still ART-naïve. At their
enrollment, subjects provide written informed consent to include
their clinical and laboratory data in the ICONA database for
scientiﬁc purposes.
The ICONA database collects the method of VL quantiﬁcation
and the corresponding detection limit; this information was
available for the analyses and used to correctly classify as
detectable or undetectable the recorded VL values. VL values >
50copies/mL were classiﬁed as detectable; VL values< 50copies/
mL or below the detection limit in use in each center were
classiﬁed as undetectable.
Two groups of treated HIV-1 subjects were retrospectively
identiﬁed based on the recorded VL determinations: subjects with
PDVL at and between the 2 considered time-points; subjects with
PU VL at and between the 2 considered time-points. Patients
treated with maraviroc were excluded from this analysis.
In both groups, the ﬁrst sample was the nearest to the ART
initiation (and approximately at least 6 months after starting),
while the second sample was taken approximately 2 years after
the date of ﬁrst sample, with a median interval between the 2
samples of 22.9 (20–28.5) months.
Co-receptor tropism was determined on HIV-RNA from
plasma samples in PD subjects and on proviral DNA extracted
from PBMC samples in PU subjects.2A single polymerase chain reaction (PCR) product per sample
was subjected to standard population sequencing. Sequences
were analyzed with Seqscape software v2.5 (Applied Biosystems,
Foster City, CA) as previously described.[25–27] Nucleotide
mixtures were considered if the second highest peak in the
electropherogram was >25%. V3 sequences with more than 8
nucleotide mixtures were discarded. The V3 sequences are
available on request.
Co-receptor tropism was inferred with the geno2pheno
algorithm setting the false positive rate (FPR) at 10% for plasma
samples and 20% for PBMC samples,[1] based on previous
studies[28,29] showing concordant results in the determination of
co-receptor tropism for the same individual whether plasma RNA
or proviral DNAwas used.Co-receptor tropism for all PDpatients
was determinedonlyonplasmaRNAat either time-point; similarly
in PU patients, co-receptor tropism was assessed only on proviral
DNA at either time-point. Clonal prediction was employed
for classifying sequences. Clinical isolates were classiﬁed as R5
if FPR >10% (RNA) or >20% (DNA) and non-R5 if FPR
<10% (RNA) or <20% (DNA). Non-R5 tropism included either
R5/X4-coreceptors (dual or mixed tropism) and X4-coreceptor.
Baseline for the statistical analysis used to estimate the rate of
tropism switch and factors associated with switch was deﬁned as
the date of the ﬁrst sample (T1).
A co-receptor switch (from R5 to non-R5 or from non-R5 to
R5) deﬁned an unstable tropism and was considered to occur if
the HIV tropism classiﬁcation at the second time-point (T2)
differed from that observed at T1, otherwise tropism was
considered as stable (R5 or non-R5 at both time-points).
Disease progression was deﬁned as the occurrence of a new
clinical acquired immune deﬁciency syndrome (AIDS)-deﬁning
event or death; time to disease progression was calculated as the
time elapsed since T2 up to the ﬁrst new AIDS-deﬁning event
or death or last available clinical follow-up visit (whichever
occurred ﬁrst).2.1. Statistical analysis
Patients’ main characteristics were described as median (inter-
quartile range, IQR) for continuous variables or proportions for
categorical variables. Continuous variables were compared using
the Wilcoxon rank sum test or the Kruskal–Wallis test, as
appropriate. Differences between proportions were tested by the
x2 or Fisher exact test.
The incidence rate of co-receptor tropism switch was
calculated as the number of switches per 100 person-years of
follow-up (PYFU); separate estimates were calculated for switch
from non-R5 to R5-tropic viruses and from R5 to non-R5-tropic
viruses. Rates were reported with the corresponding 95%
conﬁdence interval (95% CI).
Univariate and multivariate Poisson regression models were
performed to estimate the risk of tropism switch in relation to the
subjects’ virological group (PD vs PU) and other baseline
characteristics. Separate models were used to identify predictors
of the risk of switch to R5-tropic virus and of the risk of switch to
non-R5-tropic virus, and estimates were presented as relative risk
(RR) with 95% CI; covariates with a P-value 0.20 in the
univariate analysis were considered for entry into the multivari-
ate models in addition to age, sex, baseline CD4+, and subjects’
virological group (PU vs PD). Collinearity between variables was
assessed by means of the variance inﬂation factors (VIF); the
largest VIF for a single covariate was 1.6, indicating that all
variables could be included in the model together.
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matrix, were used to examine CD4+ trend during the T1–T2
interval or from baseline (T1) until disease progression or last
available visit, whichever occurred ﬁrst; estimates of CD4+
trajectories over time (slope± standard error) were calculated
using random intercept and random slope of months of follow-up
to model the within-patient errors.
Univariate and multivariate Cox proportional hazard models
were calculated to evaluate the inﬂuence of co-receptor tropism
switch and other covariates on the risk of disease progression
(occurrence of a new AIDS-deﬁning event or death since T2); the
contribution of each covariate was expressed by the hazard ratio
(HR) with the corresponding 95% CI. The multivariate model
included demographic variables, hepatitis C virus (HCV) co-
infection (a factor with a potential impact on disease progression)
and those confounders with a P0.10 in the univariate analysis:
age, sex, HCV co-infection, AIDS diagnosis before T2, CD4 nadir
before T2, years of ART treatment, co-receptor tropism switch,
current CD4+, current HIV-RNA.Table 1
Baseline demographic, clinical, and laboratory characteristics of 195
Characteristic Total (n=195)
Age, y 37 (33–42)
Males 134 (69.0%)
Race
White 184 (94.4%)
Other 11 (5.6%)
Mode of HIV transmission
IDU 70 (35.9%)
MSM 42 (21.5%)
Heterosexual 73 (37.4%)
Other 10 (5.1%)
HCV-Ab
Positive 68 (34.9%)
Negative 112 (57.4%)
Unknown 15 (7.7%)
HbsAg
Positive 12 (6.1%)
Negative 169 (86.7%)
Unknown 14 (7.2%)
Previous diagnosis of AIDS
Yes 31 (15.9%)
No 164 (84.1%)
Nadir CD4+ before baseline (cells/mL) 259 (105–403)
200 74 (38.0%)
>200 121 (62.0%)
Type of ART
NRTI-based 52 (26.7%)
NNRTI-based 37 (19.0%)
PI-based 106 (54.3%)
Years since ﬁrst HIV positive test 3.7 (1.3–9.9)
Calendar year of ART initiation 1998 (1997–2001)
Months since ART initiation 10.0 (5.2–16.3)
Baseline calendar year 1999 (1998–2002)
HIV-RNA (copies/mL) 2233 (60–14,800)
CD4+ (cells/mL) 448 (257–653)
CD8+ (cells/mL) 965 (706–1323)
CD4+/CD8+ ratio 0.43 (0.27–0.63)
Hemoglobin at baseline (g/dL) 14.1 (13.0–14.8)
Results are median (IQR) or frequency (%), as appropriate.
ART=antiretroviral therapy, IDU= intravenous drug users, MSM=men who have sex with men, NNRTI=n
persistently detectable viral load between T1 and T2, PI=protease inhibitor, PU=persistently undetect
∗
By Wilcoxon rank sum test.
† By x2 or Fisher exact test, as appropriate.
3In all statistical analyses, a P<0.05 was considered statistically
signiﬁcant. The analyses were performed using SAS Software,
release 9.2 (SAS Institute, Cary, NC).3. Results
3.1. Patients and their characteristics
HIV-1 V3 loop sequences were successfully obtained from 195
subjects (124 PD, 71 PU) satisfying the study inclusion criteria at
baseline (T1) and at T2; baseline was 10.0 (5.2–16.3) months
after the date of ART initiation.
The main baseline characteristics of PD and PU subjects are
shown in Table 1; PD subjects were younger, more frequently
intravenous drug users, more likely to be co-infected with HCV
(41.1%vs 23.9%, P=0.01), with an earlier calendar year of ART
initiation, more frequently treated with a nucleoside reverse
transcriptase inhibitor (NRTI)-based regimen (37.9% vs 7.0%,
P< .001), as compared with PU patients. The median number ofHIV-1 treated subjects included in the analysis.
PD patients (n=124) PU patients (n=71) P
36 (32–40) 40 (34–45) 0.01
∗
85 (68.6%) 49 (69.0%) 0.95†
>0.99†
117 (94.4%) 67 (94.4%)
7 (5.6%) 4 (5.6%)
0.01†
55 (44.4%) 15 (21.1%)
21 (16.9%) 21 (29.6%)
43 (34.7%) 30 (42.3%)
5 (4%) 5 (7%)
0.01†
51 (41.1%) 17 (23.9%)
62 (50.0%) 50 (70.4%)
11 (8.9%) 4 (5.6%)
0.54†
9 (7.2%) 3 (4.2%)
104 (83.9%) 65 (91.5%)
11 (8.9%) 3 (4.2%)
0.16†
16 (12.9%) 15 (21.1%)
108 (87.1%) 56 (78.9%)
308 (148–428) 209 (73–332) 0.01
∗
39 (31.5%) 35 (49.3%) 0.02†
85 (68.6%) 36 (50.7%)
<0.001†
47 (37.9%) 5 (7.0%)
15 (12.1%) 22 (31.0%)
62 (50.0%) 44 (62.0%)
5.1 (1.4–10.9) 2.8 (1.2–7.9) 0.14
∗
1998 (1997–1998) 2001 (1998–2004) <0.001
∗
6.7 (4.7–12.9) 11.8 (8.6–23.6) <0.001
∗
1998 (1998–1999) 2001 (1999–2005) <0.001
∗
9900 (2400–36,950) 50 (50–50) <0.001
∗
443 (232–625) 468 (297–658) 0.26
∗
949 (757–1335) 1054 (691–1271) 0.87
∗
0.42 (0.26–0.57) 0.49 (0.31–0.68) 0.07
∗
14.0 (12.6–14.6) 14.4 (13.8–15.3) 0.01
∗
on-nucleoside reverse transcriptase inhibitor, NRTI=nucleoside reverse transcriptase inhibitor, PD=
able viral load between T1 and T2.
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(6–10) in PD and PU subjects, respectively (P< .001). In PD
subjects, HIV-RNA area-under-the-curve between the 2 time-
points was 3.82 (3.31–4.26) log10copies/mL/d. Overall, subtype
B HIV-1 was assigned to 183 patients [117/124 (94%) in PD and
66/71 (93%) in PU, P=0.76].3.2. HIV-1 tropism switch
At baseline (T1), 93 (75%) PD patients were predicted to harbor
an R5 virus in comparison to 46 PU (65%) subjects, with no
signiﬁcant difference (P=0.14). At T2, there were 90 (73%) PD
subjects with an R5 virus after a median follow-up of 22.1
(19.2–24.7) months and 43 (61%) PU subjects had an R5 strain
after a median follow-up of 24.4 (21.0–31.6) months (difference
not statistically signiﬁcant: P=0.11).
There were 101 (81%) PD and 58 (82%) PU subjects with
stable co-receptor tropism and 23 (19%) PD and 13 (18%) PU
subjects experienced a co-receptor tropism switch between the 2
time-points (Fig. 1). The rate of co-receptor switch was similar
between PD and PU subjects (Fig. 1). Among PD subjects, the
switch was mainly from a non-R5 to an R5 strain (P=0.04) while
no difference was found among PU subjects (P=0.81).
No association was found between all the considered baseline
demographic, clinical, and laboratory characteristics or the
subjects’ group (i.e., being PD or PU) with the risk of tropism
switch to R5, while nadir CD4+ before T1 was the only factor
associated with the risk of tropism switch to non-R5 [adjustedNon-R5 tropic virus at baseline (T1
Overall (n=56) PD  (n=31) PU  (n=25) 
False posive rate at baseline (T1), 
median (IQR) 
1.7 (0-6-5.8) 1.8 (0.5-5.3) 1.7 (0.6-7.1) 
False posive rate at  T2, median 
(IQR) 
  
3.7 (1.7-19.5) 
  
4.1 (1.7-31.1) 
  
2.2 (1.7-7.1) 
Time interval between the 2 me 
points (years), median (IQR) 
  
2.1 (1.9-2.6) 
  
1.9 (1.7-2.5) 
  
2.1 (2.0-2.7) 
Number of paents with co-
receptor  switch 
15 10 5 
PYFU 127 65 62 
Rate (95% CI) of co-receptor  
switch (per 100-PYFU) 
  
11.8 (6.6-18.6) 
  
15.4 (7.3-26.4) 
  
8.1 (2.5-16.7) 
Abbreviaons: PD, persistently detectable paents; PU, persistently undetectable paents; IQR, in
a by Wilcoxon rank sum test;   
b by Poisson regression. Rate comparisons (switch to non-R5-tropic virus vs switch to R5-tropic virus): am
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Figure 1. Co-receptor tropism switch in subjects receiving antiretroviral therapy (A
4RR (per 100-cells/mL higher)=0.55, 95% CI: 0.35–0.86, P=
0.01] (Table 2).
When PD and PU patients were considered separately, no
association was observed between all the considered factors and
the risk of tropism switch to R5-tropic virus (data not shown) or
the risk of switch to non R5-tropic virus (Table 3).
We explored the association between co-receptor switch and
changes in CD4+ and VL during the T1–T2 time interval
(Table 4): a less favorable CD4+ trend was observed in subjects
with tropism switch in comparison to patients with stable
tropism. Results were similar when restricting to the switch from
a non-R5 to an R5 strain or vice versa.3.3. Association between co-receptor switch and HIV-1
disease progression
After a median time of 5.4 (2.5–9.3) years from T2, 26 (13%)
patients developed at least one AIDS event or died: 22/124 (18%)
among the PD group and 4/71 (6%) among PU subjects,
respectively (P=0.02). Among the 22 PD subjects, 11 patients
had at least one AIDS event and 17 patients died (11 without
AIDS events); among PU subjects, 2 patients had new AIDS
events, 2 patients died. Clinical details of PD and PU subjects with
disease progression are reported in Table 5.
PD subjects showed a faster disease progression and were
associated with a higher risk of disease progression as
compared with PU subjects (unadjusted HR=3.09, 95% CI:
1.06–9.00, P=0.04].) R5 tropic virus at baseline (T1) 
p-value Overall (n=139) PD  (n=93) PU  (n=46) p-value 
0.691a 48.7 (28.8-74.4) 44.4 (23.9-68.6) 59.1 (36.2-77.6) 0.026a 
0.189a 
  
35.2 (19.1-65.4) 
  
31.6 (17.1-51.8) 
  
43.3 (24.7-73.6) 
0.035a 
0.010a 
  
1.8 (1.6-2.2) 
  
1.8 (1.6-2.0) 
  
1.9 (1.6-2.5) 
0.069a 
21 13 8 
- 288 188 100 - 
0.383c 
  
7.3 (4.2-10.4) 
  
6.9 (3.7-11.2) 
  
8.0 (3.4-14.5) 
0.627c 
terquarle range; 95% CI, 95% conﬁdence interval; PYFU, person years  of follow-up. 
ong failing paents: p=0.047; among suppressed paents: p=0.806. 
5 Switch to non-R5 from R5
PD PU
15% 16%14%
RT) with persistently detectable (PD) or persistently undetectable (PU) viral load.
Table 2
Poisson regression: unadjusted and adjusted relative risk of co-receptor switch in the 195 HIV-1 treated subjects considered in the
analysis.
Risk of switch to R5-tropic virus (n=56) Risk of switch to non-R5-tropic virus (n=139)
Characteristic
Unadjusted
RR (95% CI) P
Adjusted
RR (95% CI) P
Unadjusted
RR (95% CI) P
Adjusted
RR (95% CI) P
Age (per 10-years older) 0.87 (0.42–1.80) 0.71 0.88 (0.42–1.85) 0.73 1.06 (0.77–1.44) 0.74 1.50 (0.85–2.64) 0.17
Sex
Males vs females 0.94 (0.32–2.75) 0.91 0.98 (0.30–3.22) 0.97 0.98 (0.57–1.66) 0.92 0.86 (0.32–2.31) 0.76
Race
White vs other NA
∗
NA
∗
– – 0.51 (0.23–1.13) 0.10 0.28 (0.07–1.13) 0.10
Mode of HIV transmission 0.66 – – 0.74 – –
IDU 0.96 (0.26–3.56) 0.95 0.80 (0.45–1.43) 0.45
MSM 1.60 (0.49–5.26) 0.44 0.85 (0.43–1.68) 0.64
Heterosexual Ref – Ref –
Other NA† NA† 1.06 (0.37–3.03) 0.92
HCV-Ab 0.39 – – 0.93 – –
Positive 0.41 (0.09–1.86) 0.25 0.96 (0.56–1.62) 0.87
Negative Ref – Ref –
Unknown 1.26 (0.28–5.67) 0.77 0.83 (0.30–2.33) 0.72
HbsAg 0.18 0.23 0.54 – –
Positive 2.63 (0.71–9.72) 0.15 2.42 (0.62–9.47) 0.20 1.24 (0.45–3.43) 0.68
Negative Ref – Ref – Ref –
Unknown 2.95 (0.80–10.9) 0.11 2.84 (0.74–11.0) 0.13 0.52 (0.17–2.13) 0.36
Previous diagnosis of AIDS – –
Yes vs no 1.42 (0.45–4.47) 0.56 – – 1.58 (0.86–2.92) 0.14
Nadir CD4+ prior to
baseline (per 100-cells/
mL higher)
1.03 (0.82–1.28) 0.81 – – 0.84 (0.73–0.97) 0.02 0.55 (0.35–0.86) 0.01
>200 vs 200 cells/
mL
0.88 (0.31–2.50) 0.81 0.60 (0.37–0.99) 0.04
Type of ART 0.96 – – 0.81 – –
NRTI-based 1.00 (0.29–3.43) >0.99 0.83 (0.46–1.50) 0.54
NNRTI-based 1.19 (0.35–4.08) 0.78 0.87 (0.47–1.64) 0.68
PI-based Ref – Ref –
Years since ﬁrst HIV
positive test (per year
longer)
0.98 (0.88–1.08) 0.67 – – 1.02 (0.97–1.07) 0.48 – –
Calendar year of ART
initiation (per year
longer)
1.05 (0.89–1.24) 0.58 – – 1.03 (0.95–1.12) 0.41 – –
Months since ART
initiation (per
12-months longer)
1.08 (0.59–1.97) 0.81 – 0.97 (0.76–1.24) 0.83 – –
Baseline calendar year
(per year increase)
1.05 (0.90–1.23) 0.56 – – 1.03 (0.96–1.12) 0.42 – –
Subjects’ virological group
(PD vs PU)
1.73 (0.59–5.06) 0.32 1.49 (0.49–4.51) 0.49 0.74 (0.45–1.23) 0.24 1.67 (0.52–5.33) 0.38
Baseline HIV-RNA (per
log10 copies/mL higher)
1.29 (0.87–1.92) 0.20 – – NE –
Baseline CD4+ (per
100-cells/mL higher)
1.01 (0.87–1.18) 0.88 0.99 (0.82–1.18) 0.87 0.93 (0.85–1.03) 0.15 1.34 (0.98–1.84) 0.07
Baseline CD8+ (per
100-cells/mL higher)
0.94 (0.83–1.07) 0.35 – – 0.97 (0.92–1.02) 0.27
Baseline CD4+/CD8+ ratio
(per 0.2-unit higher)
1.09 (0.80–1.48) 0.59 – – 0.76 (0.52–1.11) 0.16 0.76 (0.42–1.39) 0.35
Baseline hemoglobin (per
g/dL higher)
0.76 (0.45–1.28) 0.30 – – 1.07 (0.88–1.30) 0.52
ART=antiretroviral therapy, IDU= intravenous drug users, MSM=men who have sex with men, NA=not applicable, NE=not evaluated (because all suppressed patients had undetectable HIV-RNA at baseline),
NNRTI=non-nucleoside reverse transcriptase inhibitor, NRTI=nucleoside reverse transcriptase inhibitor, PD=persistently detectable patients, PI=protease inhibitor, PU=persistently undetectable patients,
Ref= reference, RR= relative risk.
∗
No switch to R5-tropic virus occurred among subjects with non-white race.
† No switch to R5-tropic virus occurred among subjects with other mode of HIV transmission.
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Table 3
Poisson regression: unadjusted and adjusted relative risk of switch to non-R5-tropic virus in the 139 HIV-1 treated subjects with an R5-
tropic virus at baseline.
PD patients (n=93) PU patients (n=46)
Characteristic Unadjusted RR (95% CI) P Adjusted RR (95% CI) P Unadjusted RR (95% CI) P Adjusted RR (95% CI) P
Age (per 10-years older) 0.93 (0.44–1.95) 0.85 0.72 (0.32–1.63) 0.43 1.98 (1.02–3.82) 0.04 1.42 (0.63–3.21) 0.40
Sex
Males vs females 1.11 (0.34–3.60) 0.86 1.35 (0.38–4.75) 0.63 0.70 (0.17–2.95) 0.63 0.78 (0.16–3.75) 0.76
Previous diagnosis of AIDS
Yes vs no 4.13 (1.35–12.64) 0.01 1.55 (0.36–6.61) 0.55 0.88 (0.11–7.18) 0.91 – –
Nadir CD4+ before
baseline (per 100-
cells/mL higher)
0.60 (0.41–0.88) 0.01 0.63 (0.30–1.36) 0.24 0.76 (0.48–1.20) 0.20 0.54 (0.26–1.13) 0.09
Baseline calendar year
(per year increase)
1.05 (0.81–1.36) 0.71 – – 1.23 (0.99–1.53) 0.07 1.13 (0.87–1.46) 0.36
Baseline HIV-RNA (per
log10 copies/mL
higher)
1.68 (0.93–3.03) 0.09 1.23 (0.63–2.40) 0.55 NE – NE –
Baseline CD4+ (per
100-cells/mL higher)
0.73 (0.56–0.95) 0.02 1.27 (0.71–2.25) 0.43 1.02 (0.85–1.22) 0.83 1.24 (0.91–1.70) 0.19
Baseline CD4+/CD8+
ratio (per 0.2-unit
higher)
0.42 (0.22–0.80) 0.01 0.54 (0.18–1.61) 0.24 1.11 (0.76–1.60) 0.62 – –
Race, mode of HIV transmission, HCV-Ab, HbsAg, years since HIV positive test, calendar year of ART initiation, months since ART initiation, baseline CD8+, and baseline hemoglobin were also tested and did not
inﬂuence the risk of switch to non-R5-tropic virus either in persistently detectable (PD) or undetectable patients (PU).
95% CI=95% conﬁdence interval, NE=not evaluated (as all suppressed patients had undetectable HIV-RNA at baseline), PD=persistently detectable patients, PU=persistently undetectable patients,
RR= relative risk.
Castagna et al. Medicine (2016) 95:44 MedicinePatients with tropism switch appeared to have faster disease
progression rather than those with stable R5 or non-R5 co-
receptor tropism and the risk of disease progression was higher
among subjects with tropism switch (to R5 or non-R5) in
comparison to those with stable tropism (R5 or non-R5) (HR=
2.39, 95% CI: 1.03–5.54, P=0.04].
At multivariate analysis, the risk of disease progression was
more likely in older subjects, in subjects with an AIDS diagnosis
before T2, with a lower CD4+ count nadir before T2, with lowerTable 4
Immuno-virological trend between the 2 time points according to co
Crude CD4+ slope (cells/mL per
Characteristic Estimate (standard error)
∗
Subjects’ virological group
PD patients 0.13 (± 0.74)
PU patients 4.78 (± 0.89)
Co-receptor switch
Stable non-R5 virus 3.09 (± 1.50)
Switch to R5 virus 2.75 (± 2.55)
Stable R5 virus 1.78 (± 0.69)
Switch to non-R5 virus 0.36 (± 1.61)
Stable virus (non-R5 or R5) 2.18 (± 0.66)
Switch to R5 or to non-R5 virus 1.51 (± 1.37)
Co-receptor switch among PD patients
Stable virus (non-R5 or R5) 0.23 (± 0.82)
Switch to R5 or to non-R5 virus 0.26 (± 1.72)
Co-receptor switch among PU patients
Stable virus (non-R5 or R5) 5.00 (± 0.99)
Switch to R5 or to non-R5 virus 3.90 (± 2.06)
AUC= area under the curve, IQR= interquartile range, NE=not evaluated (because all suppressed patients
persistently detectable patients, PU=persistently undetectable patients.
∗
By univariate mixed linear model.
† By Wilcoxon rank sum test.
6current CD4+, with higher current VL, and in subjects with co-
receptor switch rather than those with stable tropism (Table 6).4. Discussion
The dynamics of co-receptor tropism switch in HIV-1 infected
subjects under ART pressure remain poorly explored. Our
ﬁndings show that in approximately 2 years of follow-up under
ART, co-receptor usage is stable in 80% of cases, either in case of-receptor switch and patients’ virological group.
month) HIV-RNA AUC (log10 copies/mL per day)
P
∗
Median (IQR) P†
<0.001 3.82 (3.31–4.26) <0.001
1.69 (1.69–1.69)
0.07 2.38 (1.69–3.80) 0.35
3.76 (1.69–4.24)
0.04 3.26 (1.69–3.95) 0.85
3.53 (1.69–4.26)
0.01 3.25 (1.69–3.89) 0.51
3.57 (1.69–4.25)
>0.99 3.67 (3.27–4.25) 0.02
4.13 (3.61–4.89)
<0.001 1.69 (1.69–1.69) NE
1.69 (1.69–1.69)
with or without co-receptor shift had always undetectable HIV-RNA between the two time points), PD=
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Table 6
Cox proportional hazard models: unadjusted and adjusted relative risk of HIV disease progression in the 195 HIV-1 treated subjects.
Univariate analysis Multivariate analysis
Characteristic Unadjusted HR (95% CI) P Adjusted HR (95% CI) P
Age (per 10-years older) 1.10 (0.88–1.38) 0.40 1.74 (1.24–2.44) 0.01
Sex
Males vs females 1.08 (0.48–2.45) 0.86 0.67 (0.20–2.29) 0.53
Years of HIV infection (per 5-years longer) 0.90 (0.62–1.32) 0.60 – –
Years of ART (per 5-years longer) 0.50 (0.24–1.00) 0.05 0.61 (0.22–1.64) 0.32
HCV co-infection
Yes vs no 0.80 (0.35–1.85) 0.60 0.58 (0.17–1.95) 0.38
AIDS diagnosis prior to T2
Yes vs no 2.69 (1.18–6.12) 0.02 5.86 (1.51–22.75) 0.01
Nadir CD4+ before T2 (per 100-cells/mL higher) 0.83 (0.66–1.04) 0.10 0.75 (0.59–0.94) 0.01
Calendar year of T2 (per year increase) 0.88 (0.73–1.06) 0.17 – –
Current HIV-RNA (per log10 copies/mL higher) 1.99 (1.48–2.66) <0.001 1.59 (1.03–2.47) 0.04
HIV-RNA between T1 and T2
PD vs PU 3.09 (1.06–9.00) 0.04 – –
CD4+ at T2 (per 100-cells/mL higher) 0.77 (0.65–0.92) 0.01 – –
Current CD4+ (per 100-cells/mL higher) 0.49 (0.38–0.64) <0.001 0.55 (0.40–0.75) <0.001
Viral tropism
Switch vs stable 2.39 (1.03–5.54) 0.04 4.06 (1.20–13.80) 0.03
95% CI=95% conﬁdence interval, ART= antiretroviral therapy, HCV=hepatitis C virus, HR=hazard ratio, PD=persistently detectable patients, PU=persistently undetectable patients, T1= time-point 1,
T2= time-point 2.
Castagna et al. Medicine (2016) 95:44 Medicinesuccessful control of viral replication or in case of persistent
detectable HIV-1 viremia. Switch of HIV-1 tropism under ART
occurs in both directions, with similar rates in subjects with PD or
PU VL. Although comparisons with previous studies are difﬁcult
because of differences in study design, length of follow-up,
methodologies, and cutoffs used for co-receptor determination,
our data conﬁrmed on a large-scale ﬁndings reported in a small
case series. Switch from non-R5 to R5 virus has been described in
detail in a previous study evaluating the co-receptor usage in 40
treated failing patients with a median interval between the 2 time-
points of about 20 months.[16] Co-receptor usage was stable in
87%of patients, conversion fromX4 to R5 or fromR5 toX4was
observed in 2 patients, respectively. In another study[19] on 76
subjects with drug-resistant viremia>1000copies/mL on a stable
ART regimen for >4 months and with a median of 3 tropism
determinations (by means of a phenotypic recombinant virus
assay) over 9 months, the rate of tropism switch was about 10%
and occurred in both directions; 12% of patients infected with
R5-tropic virus at baseline switched to D/M-tropic virus by 1 year
and 11% infected with D/M-tropic virus at baseline switched to
R5 or X4-tropic virus over the same period. In this study, the
apparent tropism switches were considered as oscillations in the
amount of X4-tropic virus around the limit of assay detection.
Nevertheless, a possible alternative interpretation might be that
the switch of the co-receptor usage from X4 to R5 under ART
pressure may indeed truly occur, independently from CD4 level
and undetectability of VL. In fact, a tropism switch from non-R5
to R5 virus has also been observed in a very small series of
patients on suppressive ART[10–15] or interrupting successful
ART.[20,21]
Both R5 and non-R5 variants have been shown to persist in
viral reservoirs after prolonged suppression of plasma VL below
the detection limit.[10–15] Preliminary studies documented that
the stability of CCR5 co-receptor usage is correlated with the
maintenance of HIV-RNA <2.5copies/mL.[12] Correlation
analyses between stability of the co-receptor usage and residual8viremia, changes in proviral DNA and viral replicative
capacity[30] will provide new insights into the mechanisms of
co-receptor tropism switching in subjects with virological
suppression.
We were not able to identify predictors of tropism switch with
the only exception of CD4 nadir that was predictive of the switch
from R5 to non-R5 which might be along the lines of previous
studies showing that the presence of non-R5 virus is associated
with low nadir CD4 values.[31,32]
Results of the impact of tropism switch on long-term risk of
disease progression in subjects receiving ART are lacking.
Previous studies evaluated the risk of disease progression in
relation to co-receptor tropism by geno2pheno algorithm
determined at a single time-point yielding conﬂicting results.[9,33]
In our analysis, the presence of unstable co-receptor tropism,
irrespectively of tropism switch direction, was associated with
less favorable CD4 changes and with an increased risk of disease
progression, especially in subjects with PD VL. Our results might
contribute to explain why a substantial number of patients (62%)
diagnosed at a late stage of HIV-1 infection had only R5-tropic
virus strains.[4]
Main limitations of our study included the small number of
individuals experiencing the study outcomes and, consequently,
the power to detect predictive factors of co-receptor tropism
switch or the disease progression risk and the possibility to
evaluate if the direction of tropism switch may differently affect
the risk of disease progression. In addition, we cannot exclude
that some individuals with stable tropism might also have
experienced tropism switch before ART initiation, between ART
initiation and T1, or between T2 and the date of disease
progression.
In conclusion, HIV-1 tropism switch under ART pressure was
detected in both directions and it appears to occur with similar
rates in subjects with PD or PU VL. An unstable tropism might be
associatedwith a less favorable CD4 change and an increased risk
of disease progression, independently of established risk factors
[6] Ferrer P, Tello B, Montecinos L, et al. Prevalence of R5 and X4 variants
Castagna et al. Medicine (2016) 95:44 www.md-journal.comfor HIV progression. Larger studies are needed to conﬁrm our
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